154 results on '"Sabatine, Marc S."'
Search Results
2. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
3. Dapagliflozin and Days of Full Health Lost in the DAPA-HF Trial
4. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
5. Deficiency of lncRNA MERRICAL abrogates macrophage chemotaxis and diabetes-associated atherosclerosis
6. Rationale and design of the effect of evolocumab in patients at high cardiovascular risk without prior myocardial infarction or stroke (VESALIUS-CV) trial
7. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
8. Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
9. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
10. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
11. Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
12. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial
13. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum
14. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes
15. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF
16. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
17. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)
18. Biomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial
19. Effects of Dapagliflozin According to the Heart Failure Collaboratory Medical Therapy Score: Insights From DAPA-HF
20. Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial
21. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
22. Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
23. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials
24. Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
25. Inhibition of p38 MAP kinase in patients with ST-elevation myocardial infarction – findings from the LATITUDE–TIMI 60 trial
26. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis
27. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT
28. Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8
29. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
30. Prevalence, clinical determinants and prognostic implications of coronary procedural complications of percutaneous coronary intervention in non-ST-segment elevation myocardial infarction: Insights from the contemporary multinational TAO trial
31. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization
32. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
33. Outcomes of Women Compared With Men After Non–ST-Segment Elevation Acute Coronary Syndromes
34. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
35. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
36. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
37. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention
38. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
39. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial
40. Biomarkers in the IL-6 Pathway and Cardiovascular Outcomes in Patients With STEMI in LATITUDE-TIMI 60
41. Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients With Multivessel Coronary Disease
42. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
43. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
44. Per-Particle Cardiovascular Risk of Lipoprotein(a) vs Non-Lp(a) Apolipoprotein B-Containing Lipoproteins
45. 20 - Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition
46. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
47. Lipoprotein(a) and Benefit of Antiplatelet Therapy: Insights From the PEGASUS-TIMI 54 Trial
48. PCSK9 inhibition in patients with hypercholesterolemia
49. On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Study)
50. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.